Skip to content
lifestyle.longislandreport.org
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Nuvation Bio, Inc.
Nuvation Bio to Present Additional Updated Phase 2 Results at 2026 Society for Neuro-Oncology Annual Meeting
November 2, 2026
Nuvation Bio to Expand Pivotal Phase 3 SIGMA Study of Safusidenib for IDH1-Mutant Glioma to Six European Countries
October 29, 2026
Nuvation Bio to Report Third Quarter 2026 Financial Results and Provide Business Update on November 4, 2026
October 21, 2026
Nuvation Bio Announces FDA Approval of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in TKI-Naïve Advanced ROS1-Positive Non-Small Cell Lung Cancer
September 17, 2026
Nuvation Bio Announces New Analyses Reinforcing the Durable, Consistent Efficacy of IBTROZI® (taletrectinib) Across Key Patient Subgroups in Advanced ROS1+ NSCLC at 2026 World Conference on Lung Cancer
September 15, 2026
Nuvation Bio to Participate in Upcoming Investor Conferences
September 2, 2026
Nuvation Bio Granted FDA Fast Track Designation for Safusidenib for Treatment of IDH1-Mutant Glioma
August 20, 2026
Nuvation Bio to Present New Subgroup Analyses of Pivotal Data for IBTROZI® (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses
August 4, 2026
Nuvation Bio to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026
July 22, 2026
Nuvation Bio Announces Positive Updated Phase 2 Data and Expansion of Safusidenib Clinical Program with Two New Studies to Explore Broad Spectrum of IDH1-Mutant Glioma
July 20, 2026
1
2
Next Page
→